

On-line Table: Demographics, clinical features, and MRI parameters of HC and patients with PD with and without FOG

	HC (<i>n</i> = 12) (mean ± SD)	FOG+ (<i>n</i> = 12) (mean ± SD)	FOG− (<i>n</i> = 12) (mean ± SD)	<i>P</i> Value
Age	65.5 ± 6.17	66.83 ± 4.78	66.42 ± 6.32	.857 ^a
Gender (M/F)	7:5	8:4	8:4	.743 ^b
Disease duration (yr)	N/A	5.80 ± 2.29	6.50 ± 2.88	.667 ^a
H&Y stage	N/A	1.83 ± 0.44	1.73 ± 0.34	.645 ^b
UPDRS I	N/A	2.25 ± 1.6	1.64 ± 1.80	.536
UPDRS II	N/A	11.33 ± 3.98	6.36 ± 5.28	.531
UPDRS III	N/A	18.00 ± 9.18	12.82 ± 7.56	.018 ^c
UPDRS IV	N/A	3.08 ± 1.78	1.73 ± 1.49	.157
Symptom-dominant side (right/left)	N/A	4/8	4/8	.062
Tremor subscore ^d	N/A	3.27 ± 4.40	2.27 ± 1.55	.667
PIGD subscore ^e	N/A	4.27 ± 1.79	1.54 ± 2.88	.491
PIGD subscore without item 14 (freezing) score	N/A	2.81 ± 1.66	1.54 ± 2.88	.016 ^c
FOG-Q score	N/A	12.17 ± 2.98	3.36 ± 3.98	.220
DA agonists dose equivalent to levodopa dosage (mg daily) ^f	N/A	325.00 ± 131.76	311.11 ± 176.38	.001 ^c
Daily levodopa dose (mg daily) ^g	N/A	602.78 ± 338.30	579.55 ± 325.35	.847
GM volume (mL)	860 ± 25	807 ± 25	851 ± 23	.878
WM volume (mL)	643 ± 10	649 ± 13	675 ± 15	.339 ^a
CSF volume (mL)	245 ± 11	260 ± 13	242 ± 10	.223 ^b
TIV (mL)	1749 ± 22	1727 ± 21	1768 ± 24	.266 ^a
				.211 ^b
				.500 ^a
				.199 ^b
				.967 ^a
				.221 ^b

Note:—N/A indicates not applicable; DA, dopamine agonist; H&Y, Hoehn and Yahr; TIV, total intracranial volume; PIGD, postural instability gait disturbances.

^a HC versus patients with PD.

^b Patients with FOG+ versus those with FOG−.

^c Significant.

^d Tremor subscore represents the sum of the following UPDRS items: 16, 20, 21.

^e PIGD subscore represents the sum of the following UPDRS items: 13, 14, 15, 29, 30.

^f Eleven of 12 patients with FOG+ and 10/12 patients with FOG− were treated with DA at commonly used dosages.

^g Ten of 12 patients with FOG+ and 11/12 patients with FOG− were treated with levodopa.